Back to Search
Start Over
Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients.
- Source :
-
Expert review of hematology [Expert Rev Hematol] 2017 Jun; Vol. 10 (6), pp. 543-550. Date of Electronic Publication: 2017 May 24. - Publication Year :
- 2017
-
Abstract
- Introduction: Febrile neutropenia (FN) represents a life-threatening complication in hematological malignancies. Its etiology is most often due to infections even though FN of other origins, such as tumor-related fever and non-infectious inflammation, should rapidly be ruled out. Initially, C-reactive protein and, more recently, procalcitonin (PCT) have been proposed as useful biomarkers for differential diagnosis. PCT was shown to be a good biomarker of bacterial infections and their clinical outcomes. Definition of standard cut-offs and design of PCT-guided treatment protocols remain however to be defined. Areas covered: In this review, highlights on the current clinical use of PCT and its potential role as a diagnostic tool have been discussed by a panel of physicians from different areas of expertise. We provide current clinical evidence that PCT has been shown to be a reliable biomarker to differentiate fever of bacterial origin from other causes. Moreover, the Authors convened to a round-table to discuss their 'real-life experience' and offer their recommendations by a Delphi survey. Expert commentary: PCT has an important clinical role in FN. Issues such as the validation of a specific decision algorithm that includes PCT to monitor antibiotic choice and treatment duration will be addressed in prospective studies.
Details
- Language :
- English
- ISSN :
- 1747-4094
- Volume :
- 10
- Issue :
- 6
- Database :
- MEDLINE
- Journal :
- Expert review of hematology
- Publication Type :
- Academic Journal
- Accession number :
- 28471695
- Full Text :
- https://doi.org/10.1080/17474086.2017.1326813